Rhymer A R, Sromovsky J A, Dicenta C, Hart C B
Curr Med Res Opin. 1983;8 Suppl 2:62-71. doi: 10.1185/03007998309109825.
A multi-centre, double-blind trial was carried out in 272 out-patients with osteoarthritis of the knee(s) to compare the efficacy and tolerability of 'Osmosin', the osmotic release system for indomethacin (7 mg per hour for approximately 10 hours), with that of conventional indomethacin capsules (25 mg 3-times daily) over a period of 12 weeks. The results, as assessed by the subjective and objective clinical variables and laboratory parameters studied, showed that 'Osmosin' provided not only comparable overall therapeutic response but also a preferable tolerability profile to the indomethacin capsule regimen. At completion of the study, 89% of patients treated with 'Osmosin' were being maintained on one dose daily, and 80% of these patients were rated as having a good or excellent response. The results indicate that 'Osmosin' given once daily is a well-tolerated and efficacious therapy for patients with osteoarthritis.
一项多中心、双盲试验在272名膝关节骨关节炎门诊患者中进行，以比较吲哚美辛渗透释放系统“Osmosin”（每小时7毫克，持续约10小时）与传统吲哚美辛胶囊（25毫克，每日3次）在12周内的疗效和耐受性。根据所研究的主观和客观临床变量及实验室参数评估，结果显示“Osmosin”不仅提供了相当的总体治疗反应，而且与吲哚美辛胶囊方案相比耐受性更佳。在研究结束时，接受“Osmosin”治疗的患者中有89%维持每日一剂，其中80%的患者被评为反应良好或优秀。结果表明，每日一次给予“Osmosin”对骨关节炎患者是一种耐受性良好且有效的治疗方法。
